Physician
After Hours Clinic INC
After Hours Clinic INC was paid $5.59M by Medicaid between Jan 2018 and Dec 2024, across 26 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 42% of everything it billed.
33Billing provider infoAFTER HOURS CLINIC INC
JASPER, AL 35501
JASPER, AL 35501
33aNPI1215958103assigned 07/23/2006
33bProvider typeFamily Medicine Physician
28Total paid$5.59M
24GClaims237,229
24DCodes billed26
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Alabama
Rank by total paid#5 of 455
Median peer was paid$57K
This provider vs. median98×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,971 | $543K | |
| 2019 | 32,886 | $728K | |
| 2020 | 18,514 | $519K | |
| 2021 | 32,014 | $829K | |
| 2022 | 43,839 | $1.05M | |
| 2023 | 46,204 | $1.13M | |
| 2024incomplete | 37,801 | $794K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 42% | 34,075 | 31,399 | $2.34M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 26,886 | 24,948 | $1.27M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 9.5% | 20,484 | 19,142 | $530K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.3% | 54,159 | 50,140 | $465K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.5% | 36,506 | 17,001 | $363K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.0% | 18,067 | 16,943 | $221K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.5% | 19,222 | 17,637 | $195K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 1,549 | 1,410 | $99K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,453 | 1,388 | $46K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 682 | 647 | $22K |
| 99051 | <1% | 806 | 768 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,097 | 10,277 | $12K |
14 more codes
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,579 | $4K |
| 86308 | <1% | 407 | $2K | |
| 81002 | <1% | 661 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 170 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 900 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 51 | $1K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 30 | $587.10 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $552.70 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 69 | $446.40 |
| 82948 | <1% | 86 | $228.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30 | $5.22 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 41 | $0.24 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 105 | $0.04 |
| 36416 | 0% | 100 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLACE, DORIS (OFFICE MANAGER)